Form EFFECT EyePoint Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Mizuho Securities Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Buy
November 1, 2023 4:05 PM EDTMizuho Securities analyst Graig Suvannavejh initiates coverage on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) with a Buy rating and a price target of $20.00.
The analyst comments "We initiate on EYPT at Buy/$20 (implies ~200% upside). EYPT is advancing EYP-1901 as a novel treatment for retinal diseases,... More
